Humana Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.89%.
Did HUM Beat Earnings? Q3 2025 Results
Humana posted a stronger-than-expected third quarter, with adjusted earnings per share of $3.24 beating the $2.83 consensus estimate by 14.64% and revenue of $32.65 billion topping expectations by 1.99% on 11.1% year-over-year growth from $29.40 billion, offering some reassurance to investors who have watched the stock trade well below its 52-week high. The headline beat was supported by a sharp swing in favorable prior-period medical claims reserve development, which reached $275.00 million in Q3 2025 compared to just $24.00 million a year earlier, helping cushion a benefit ratio of 91.1% and the pressure from ongoing Medicare Advantage membership declines. On a GAAP basis, earnings came in at $1.62 per share, weighed down by $267.00 million in value creation initiative charges and a $63.00 million loss tied to the sale of Enclara Pharmacia. Looking ahead, Humana affirmed its full-year adjusted EPS guidance of approximately $17.00 and improved its individual MA membership decline forecast to roughly 425,000, citing stronger retention and better-than-expected sales recapture.
- Higher per-member Medicare premiums driven by increased direct subsidy from the Inflation Reduction Act (IRA)
- Membership growth in state-based contracts and stand-alone PDP businesses
- Stronger individual MA retention and better-than-expected sales, improving membership decline to approximately 425,000 from up to 500,000
- CenterWell Primary Care patient growth of nearly 15% YTD to 447,100 patients
- CenterWell Pharmacy strong specialty volumes and direct-to-consumer growth exceeding expectations
- Favorable prior period medical claims reserve development of $275 million in Q3 2025
- Administrative cost efficiencies from value creation initiatives
“Our strategy of putting the consumer at the heart of everything we do is working, with solid year to date performance and strong momentum heading into the Annual Election Period.”
Humana CEO, on the earnings call
Forward Guidance & Outlook
Humana affirmed FY 2025 Adjusted EPS guidance of approximately $17.00 while revising GAAP EPS guidance to approximately $12.26 from $13.77. The Insurance segment benefit ratio is expected at the top end of the 90.1%-90.5% guidance range, with Q4 expected at approximately 93.5%. Individual MA membership decline improved to approximately 425,000 from up to 500,000. The company added approximately $150 million in incremental investments for FY 2025 focused on member outcomes and network management. FY 2025 consolidated revenue guidance is at least $128 billion, with Insurance segment revenue of at least $123 billion. Operating cash flows are guided at $2.4-$2.9 billion with capital expenditures of approximately $650 million. For 2026, management expects to double individual MA pretax margin (normalizing for Stars) through pricing, clinical excellence, and operating leverage, while Star Rating declines for Bonus Year 2026 remain a headwind. The company expects improved retention and net membership growth in 2026 MA.
HUM YoY Financials
HUM Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.